- Home
- MRKR vs DALN Comparison
MRKR vs DALN Comparison
Compare MRKR & DALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRKR
- DALN
- Stock Information
- Founded
- MRKR N/A
- DALN 1954
- Country
- MRKR United States
- DALN United States
- Employees
- MRKR N/A
- DALN N/A
- Industry
- MRKR Biotechnology: Pharmaceutical Preparations
- DALN Newspapers/Magazines
- Sector
- MRKR Health Care
- DALN Consumer Discretionary
- Exchange
- MRKR Nasdaq
- DALN Nasdaq
- Market Cap
- MRKR 35.8M
- DALN 29.3M
- IPO Year
- MRKR N/A
- DALN 2008
- Fundamental
- Price
- MRKR $3.50
- DALN $5.11
- Analyst Decision
- MRKR Strong Buy
- DALN
- Analyst Count
- MRKR 1
- DALN 0
- Target Price
- MRKR $19.00
- DALN N/A
- AVG Volume (30 Days)
- MRKR 34.9K
- DALN 38.5K
- Earning Date
- MRKR 11-22-2024
- DALN 11-12-2024
- Dividend Yield
- MRKR N/A
- DALN 12.26%
- EPS Growth
- MRKR N/A
- DALN N/A
- EPS
- MRKR N/A
- DALN N/A
- Revenue
- MRKR $3,727,435.00
- DALN $128,286,000.00
- Revenue This Year
- MRKR $35.94
- DALN N/A
- Revenue Next Year
- MRKR N/A
- DALN N/A
- P/E Ratio
- MRKR N/A
- DALN N/A
- Revenue Growth
- MRKR N/A
- DALN N/A
- 52 Week Low
- MRKR $2.44
- DALN $2.98
- 52 Week High
- MRKR $6.16
- DALN $6.47
- Technical
- Relative Strength Index (RSI)
- MRKR 46.47
- DALN 50.60
- Support Level
- MRKR $3.52
- DALN $5.05
- Resistance Level
- MRKR $3.90
- DALN $6.47
- Average True Range (ATR)
- MRKR 0.40
- DALN 0.50
- MACD
- MRKR -0.08
- DALN -0.04
- Stochastic Oscillator
- MRKR 0.00
- DALN 30.26
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.
About DALN DallasNews Corporation Series A
DallasNews Corp is a local news and information publishing company in Texas with commercial printing, distribution, and direct mail capabilities, as well as a presence in emerging media and digital marketing.